Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL

Our previous clinical study achieved complete remission (CR) rates of >90% following chimeric antigen receptor T cells targeting CD19 (CART19) treatment of refractory/relapsed B cell acute lymphoblastic leukemia (r/r B-ALL); however, the influence of the leukemia burden in peripheral blood (PB) b...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Biping, Pan, Jing, Liu, Zhaoli, Liu, Shuangyou, Chen, Yunlong, Qu, Xiaomin, Zhang, Yu'e, Lin, Yuehui, Zhang, Yanlei, Yu, Xinjian, Zhang, Zhongxin, Niu, Xuansha, Luan, Rong, Ma, Ming, Li, Xiaomei, Liu, Tingting, Wu, Xi'ai, Niu, Huan, Chang, Alex H., Tong, Chunrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640733/
https://www.ncbi.nlm.nih.gov/pubmed/34901308
http://dx.doi.org/10.1016/j.omtm.2021.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640733/
https://www.ncbi.nlm.nih.gov/pubmed/34901308
http://dx.doi.org/10.1016/j.omtm.2021.10.006

Ejemplares similares